Grifols (GRFS) Other financing activities (2011 - 2020)
Grifols (GRFS) posted Other financing activities of $5.3 million for Q1 2020, down 52.75% quarter-over-quarter from $11.2 million in Q4 2019, and down 54.36% year-on-year from $11.6 million in Q2 2019.
Grifols (GRFS) Other financing activities (2011 - 2020) Analysis & Trends
Grifols (GRFS) has reported Other financing activities for 9 consecutive years, with $5.3 million the latest figure, recorded in Q1 2020.
- Other financing activities for Q1 2020 came in at $5.3 million, down 54.36% year-over-year; the trailing twelve-month figure through Mar 2020 was $27.4 million (up 185.1% YoY), and the FY2025 annual result was $43.1 million, down 22.49% from the prior year.
- Other financing activities was $5.3 million for Q1 2020 at Grifols, down from $11.2 million in the prior quarter.
- Over five years, Other financing activities peaked at $182.0 million in Q4 2017 and troughed at -$103.6 million in Q1 2017.
- Average Other financing activities over 5 years is $15.7 million, with a median of $5.3 million recorded in 2020.
- Year-over-year, Other financing activities plunged 1745.48% in 2016 and surged 2902.98% in 2017.
- Over 5 years, Other financing activities stood at $6.1 million in 2016, then surged by 2902.98% to $182.0 million in 2017, then plunged by 100.39% to -$700817.4 in 2018, then surged by 1701.54% to $11.2 million in 2019, then tumbled by 52.75% to $5.3 million in 2020.
- Per Business Quant data, the three most recent Other financing activities figures were $5.3 million in Q1 2020, $11.2 million in Q4 2019, and $11.6 million in Q1 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 5.30 Mn |
| Mar 31, 2020 | 5.30 Mn |
| Dec 31, 2019 | 11.22 Mn |
| Dec 31, 2019 | 11.22 Mn |
| Mar 31, 2019 | 11.62 Mn |
| Mar 31, 2019 | 11.62 Mn |
| Dec 31, 2018 | -700,817.41 |
| Dec 31, 2018 | -700,817.41 |
| Jun 30, 2018 | -2.48 Mn |
| Jun 30, 2018 | -2.48 Mn |
| Mar 31, 2018 | 1.18 Mn |
| Mar 31, 2018 | 1.18 Mn |
| Dec 31, 2017 | 181.96 Mn |
| Dec 31, 2017 | 181.96 Mn |
| Jun 30, 2017 | 116.86 Mn |
| Jun 30, 2017 | 116.86 Mn |
| Mar 31, 2017 | -103.56 Mn |
| Mar 31, 2017 | -103.56 Mn |
| Dec 31, 2016 | 6.06 Mn |
| Dec 31, 2016 | 6.06 Mn |